comparemela.com

Tobin Schilke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rhenman & Partners Asset Management AB Has $4 18 Million Holdings in Revance Therapeutics, Inc (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Rhenman & Partners Asset Management AB Has $4 18 Million Holdings in Revance Therapeutics, Inc (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Revance Therapeutics, Inc (NASDAQ:RVNC) Given Consensus Recommendation of Moderate Buy by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]

Analysts Set Revance Therapeutics, Inc (NASDAQ:RVNC) Price Target at $11 50

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8 00 at The Goldman Sachs Group

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8 00 at The Goldman Sachs Group
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.